Mackenzie Financial
KRSA

Mackenzie Financial’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Mackenzie Financial’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-211
Closed -$19.4K – 1540
2022
Q4 		$19.4K Buy
211
+16
+8% +$189 ﹤0.01% 1402
2022
Q3 		$23K Sell
195
-97
-33% -$1.67K ﹤0.01% 1404
2022
Q2 		$22K Buy
292
+111
+61% +$1.59K ﹤0.01% 1436
2022
Q1 		$28K Buy
+181
New +$4.36K ﹤0.01% 1386

Other funds holding KRSA

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mackenzie Financial's KRSA Position: Q1 2023 in Review

Mackenzie Financial sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q1 2023, closing a stake of 211 shares — an estimated $19.4K sold.

Mackenzie Financial first reported a position in KRSA in Q1 2022 and held it in 4 quarters. The position peaked at $28K in Q1 2022. 30 funds tracked by Wall St. Rank hold KRSA as of Q1 2023.

  • Mackenzie Financial reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Mackenzie Financial sold 211 Korsana Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $19.4K.
  • Mackenzie Financial first reported a position in Korsana Biosciences, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
  • Mackenzie Financial's Korsana Biosciences, Inc. Common Stock position peaked at $28K in Q1 2022.
  • 30 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q1 2023.

Based on Mackenzie Financial's 13F filing for Q1 2023, filed 24 Apr 2023.